Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of HBN-1 in Out-of-Hospital Cardiac Arrest
NCT04094857Phase 1Unknown
- Sponsor
- Hibernaid, Inc.
- Start
- Oct 2019
- Primary completion
- Nov 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HBN-1 in cardiac arrest (SCA) (2 arms), sponsored by Hibernaid, Inc. Primary endpoint: Characterize the safety and recommended Phase 2 loading dose infusion rate of HBN-1 at 72 hours. Status: unknown.
02
Drugs
HBN-1
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT04094857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094857.